POSA67 Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Versus Dual Therapies in Moderate-to-Very Severe COPD: United Kingdom Analysis Using the ETHOS Study
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.212
https://www.valueinhealthjournal.com/article/S1098-3015(21)02007-6/fulltext
Title :
POSA67 Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Versus Dual Therapies in Moderate-to-Very Severe COPD: United Kingdom Analysis Using the ETHOS Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02007-6&doi=10.1016/j.jval.2021.11.212
First page :
Section Title :
Open access? :
No
Section Order :
10983